blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2859895

EP2859895 - Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  31.03.2017
Database last updated on 10.07.2024
FormerExamination is in progress
Status updated on  19.12.2016
Most recent event   Tooltip31.03.2017Application deemed to be withdrawnpublished on 03.05.2017  [2017/18]
Applicant(s)For all designated states
CELGENE CORPORATION
7 Powder Horn Drive
Warren, NJ 07059 / US
[2015/16]
Inventor(s)01 / Muller, George W
P O Box 3688
Rancho
Santa Fe, CA California 92067 / US
02 / Stirling, David
3281 Round Hill Road
Branchburg, NJ New Jersey 08876 / US
03 / Chen, Roger, Shen-Chu
110 Christie Street
Edison, NJ New Jersey 08820 / US
 [2015/16]
Representative(s)Hutter, Anton, et al
Venner Shipley LLP
5 Stirling House
Stirling Road The Surrey Research Park
Guildford GU2 7RF / GB
[N/P]
Former [2015/16]Hutter, Anton, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
Application number, filing date14195487.524.07.1997
[2015/16]
Priority number, dateUS1996069025824.07.1996         Original published format: US 690258
US1996070149422.08.1996         Original published format: US 701494
US19970048278P30.05.1997         Original published format: US 48278 P
[2015/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2859895
Date:15.04.2015
Language:EN
[2015/16]
Search report(s)(Supplementary) European search report - dispatched on:EP16.03.2015
ClassificationIPC:A61K31/454, A61P37/02
[2015/16]
CPC:
A61K9/0056 (EP); A61K31/445 (EP); A61K31/454 (EP);
A61K9/0019 (EP); A61K9/2018 (EP); A61K9/48 (EP);
A61P1/00 (EP); A61P1/04 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P17/00 (EP); A61P17/02 (EP);
A61P17/04 (EP); A61P17/06 (EP); A61P19/00 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P29/00 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/08 (EP);
A61P31/12 (EP); A61P31/18 (EP); A61P31/22 (EP);
A61P33/02 (EP); A61P33/06 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P39/02 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); C07D401/04 (EP); Y02A50/30 (EP) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2015/46]
Former [2015/16]AT,  BE,  CH,  DE,  DK,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE 
TitleGerman:Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Werte[2015/16]
English:Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels[2015/16]
French:2-(2,6-dioxopipéridin-3-yl)-phtalimides et 1-oxoisoindolines substituées et procédé pour réduire les niveaux TNF alpha[2015/16]
Examination procedure29.09.2015Amendment by applicant (claims and/or description)
29.09.2015Examination requested  [2015/46]
11.07.2016Despatch of a communication from the examining division (Time limit: M04)
22.11.2016Application deemed to be withdrawn, date of legal effect  [2017/18]
20.12.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2017/18]
Parent application(s)   TooltipEP02012942.5  / EP1285916
EP09151443.0  / EP2070920
EP10183268.1  / EP2305663
EP97936295.1  / EP0925294
Fees paidRenewal fee
28.11.2014Renewal fee patent year 03
28.11.2014Renewal fee patent year 04
28.11.2014Renewal fee patent year 05
28.11.2014Renewal fee patent year 06
28.11.2014Renewal fee patent year 07
28.11.2014Renewal fee patent year 08
28.11.2014Renewal fee patent year 09
28.11.2014Renewal fee patent year 10
28.11.2014Renewal fee patent year 11
28.11.2014Renewal fee patent year 12
28.11.2014Renewal fee patent year 13
28.11.2014Renewal fee patent year 14
28.11.2014Renewal fee patent year 15
28.11.2014Renewal fee patent year 16
28.11.2014Renewal fee patent year 17
28.11.2014Renewal fee patent year 18
27.07.2015Renewal fee patent year 19
27.07.2016Renewal fee patent year 20
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US5463063  (MULLER GEORGE W [US]) [Y] 1-3 * see in particular formula 1A, column 4 *;
 [Y]WO9420085  (CHILDRENS MEDICAL CENTER [US]) [Y] 1-3 * see in particular claim 2 *;
 [YP]  - NIWAYAMA S ET AL, "POTENT INHIBITION OF TUMOR NECROSIS FACTOR-ALPHA PRODUCTION BY TETRAFLUOROTHALIDOMIDE AND TETRAFLUOROPHTHALAMIDES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (19960802), vol. 39, no. 16, doi:10.1021/JM960284R, ISSN 0022-2623, XP002048231 [YP] 1-3 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm960284r
 [T]  - NIWAYAMA S ET AL, "Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (19980501), vol. 8, no. 9, doi:10.1016/S0960-894X(98)00171-1, ISSN 0960-894X, pages 1071 - 1076, XP004137022 [T] * the whole document *

DOI:   http://dx.doi.org/10.1016/S0960-894X(98)00171-1
by applicantWO9211383
    - TRACEY ET AL., NATURE, (1987), vol. 33O, pages 662 - 664
    - HINSHAW ET AL., CIRC. SHOCK, (1990), vol. 30, pages 279 - 292
    - DEZUBE ET AL., LANCET, (1990), vol. 335, no. 8690, page 662
    - MILLAR ET AL., LANCET, (1989), vol. 2, no. 8665, pages 712 - 714
    - FERRAI-BALIVIERA ET AL., ARCH. SURG., (1989), vol. 124, no. 12, pages 1400 - 1405
    - BERTOLINI ET AL., NATURE, (1986), vol. 319, pages 516 - 518
    - JOHNSON ET AL., ENDOCRINOLOGY, (1989), vol. 124, no. 3, pages 1424 - 1427
    - CALCL, TISSUE INT. (US), (1990), vol. 46, pages 3 - 10
    - HOLLER ET AL., BLOOD, (1990), vol. 75, no. 4, pages 1011 - 1016
    - GRAU ET AL., N. ENGL. J. MED, (1989), vol. 320, no. 24, pages 1586 - 1591
    - LEIBOVICH ET AL., NATURE, (1987), vol. 329, pages 630 - 632
    - CHING ET AL., BRIT. J. CANCER, (1955), vol. 72, pages 339 - 343
    - KOCH, PROGRESS IN MEDICINAL CHEMISTRY, (1985), vol. 22, pages 166 - 242
    - PIGNET ET AL., NATURE, (1990), vol. 344, pages 245 - 247
    - BISSONNETTE ET AL., INFLAMMATION, (1989), vol. 13, no. 3, pages 329 - 339
    - BAUGHMAN ET AL., J LAB. CLIN MED., (1990), vol. 115, no. 1, pages 36 - 42
    - VEDDER ET AL., PNAS, (1990), vol. 87, pages 2643 - 2646
    - SHERRY ET AL., J. CELL BIOL., (1988), vol. 107, pages 1269 - 1277
    - MUNRO ET AL., AM. J. PATH., (1989), vol. 135, no. 1, pages 121 - 132
    - ELLIOT ET AL., NT. J. PHARMAC., (1995), vol. 17, no. 2, pages 141 - 145
    - VON DULTEMEN ET AL., GASTROENTEROLOGY, (1995), vol. 109, no. 1, pages 129 - 135
    - DUH ET AL., PROC. NAT. ACAD SCI., (1989), vol. 86, pages 5974 - 5978
    - POLL ET AL., PROC. NAT. ACAD SCI., (1990), vol. 87, pages 782 - 785
    - MONTO ET AL., BLOOD, (1990), vol. 79, page 2670
    - CLOUSE ET AL., J. IMMUNOL., (1989), vol. 142, pages 431 - 438
    - POLL ET AL., AIDS RES. HUM. RETROVIRUS, (1992), pages 191 - 197
    - ROSENBERG ET AL., "The lmmunopathogenesis of HIV Infection", ADVANCES IN IMMUNOLOGY, (1989), page 57
    - POLI ET AL., PROC. NATL. ACAD, SCI., (1990), vol. 87, pages 782 - 784
    - OSBORN ET AL., PNAS, vol. 86, pages 2336 - 2340
    - FOLKS, PNAS, (1989), vol. 86, pages 2365 - 2368
    - OSBOM ET AL., PNAS, (1989), vol. 86, pages 2336 - 2340
    - WRIGHT ET AL., J. IMMUNOL., (1988), vol. 1 1, no. 1, pages 99 - 104
    - LENARDO ET AL., CELL, (1989), vol. 58, pages 227 - 29
    - DBAIBO ET AL., J. BIOL. CHEM., (1993), vol. 177, pages 62 - 66
    - DUH ET AL., PROC. NATL. ACAD SCI., (1989), vol. 86, pages 5974 - 78
    - BACHELERIE ET AL., NATURE, (1991), vol. 350, pages 709 - 12
    - BOSWAS ET AL., J. ACQUIRED LMMUNE DEFICIENCY SYNDROME, (1993), vol. 6, pages 778 - 786
    - SUZUKI, BIOC EM. AND BIOPHYS. RES. COMM., (1993), vol. 193, pages 277 - 83
    - SUZUKI ET AL., BIOCHEM. AND BIOPHYS RES COMM., (1992), vol. 189, pages 1709 - 15
    - SUZUKI ET AL., BIOCHEM..MOL BIO. INI., (1993), vol. 31, no. 4, pages 693 - 700
    - SHAKHOV ET AL., PROC. NATL. ACAD SCI. USA, (1990), vol. 171, pages 35 - 47
    - STAAL, PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 9943 - 47
    - BEUTIER ET AL., SCIENCE, (1985), vol. 234, pages 470 - 474
    - JÖNSSON, ACTA PHARMA. SUCCFCA, (1972), vol. 9, pages 521 - 542
    - SCHRÖDER; LUBKE, The Peptides, ACADEMIC PRESS, (1965), vol. I
    - HOUBEN-WEYL, Methoden der organischen Chemic, GEORG THIEME VERLAG, (1974), vol. 15/L
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.